Interferon gamma induction in human melanoma cell/allogeneic leukocyte co-cultures is enhanced by interleukin 18 but drug resistant melanoma cells are poorer inducers of IFN-gamma.
暂无分享,去创建一个
M. Micallef | M. Kurimoto | H. Yamauchi | J. Buhagiar | S. Darmanin | R. Ellul-Micallef | M. Camilleri-Podesta | A. Inglott
[1] J. Naeyaert,et al. Understanding the trends in melanoma incidence and mortality: where do we stand? , 2000, European journal of dermatology : EJD.
[2] A. Eggermont,et al. The Emerging Role of Cytokines in the Treatment of Advanced Melanoma , 2000, Oncology.
[3] P. Queirolo,et al. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience. , 1999, Anticancer research.
[4] M. Micallef,et al. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model , 1999, Cancer Immunology, Immunotherapy.
[5] S. Melnick,et al. Multidrug resistance in human tumors--molecular diagnosis and clinical significance. , 1999, Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology.
[6] M. Hirose,et al. Cytocidal activity of PBL, LAK, and IDEC-C2B8 and expression of HLA class 1, ICAM-1, and CD20 in vincristine-resistant hematologic cell lines. , 1999, Journal of immunotherapy.
[7] M. Micallef,et al. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration , 1999, Cancer Gene Therapy.
[8] C. Ioannides,et al. Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug sensitivity. , 1998, Cancer research.
[9] A. Bhushan,et al. Drug resistance results in alterations in expression of immune recognition molecules and failure to express Fas (CD95) , 1998, Immunology and cell biology.
[10] R Khanna,et al. Tumour surveillance: Missing peptides and MHC molecules , 1998, Immunology and cell biology.
[11] T. Grogan,et al. Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins , 1997, Leukemia.
[12] A. Krishan,et al. Flow cytometric analysis of the multiple drug resistance phenotype , 1997, Leukemia.
[13] H. Okamura,et al. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[14] T. Tanimoto,et al. Interferon‐γ‐inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin‐12 for interferon‐γ production , 1996 .
[15] H. Okamura,et al. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. , 1996, Journal of immunology.
[16] H. Okamura,et al. Cloning of a new cytokine that induces IFN-γ production by T cells , 1995, Nature.
[17] T. Tanimoto,et al. Interleukin 18 induces a synergistic enhancement of interferon gamma production in mixed murine spleen cell-tumor cell cultures: role of endogenous interleukin 12. , 2000, Cancer detection and prevention.
[18] R. Johnstone,et al. Multiple physiological functions for multidrug transporter P-glycoprotein? , 2000, Trends in biochemical sciences.
[19] F. Marincola,et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.
[20] J. Wharton,et al. Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line. , 1994, Lymphokine and cytokine research.
[21] M. Poupon,et al. Drug-induced tumor progression in a rat rhabdomyosarcoma. , 1988, Advances in experimental medicine and biology.